This Government Contract opportunity from Department Of Health And Human Services was posted on July 24, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Top

Notice of Intent to Award a Sole Source Contract – Sequencing Bundibugyo virus disease (BDBV) in the 2026 outbreak

Closed

OC-2026-135667Federal

Submission Closed07/29/2026, 09:00:00 PM UTC

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 541714

New

Federal

Request for Proposals (RFP) - BARDA Vaccine Medical Countermeasures for Pandemic Influenza Preparedness & Response

Solicitation # 75A50126R00001_RFP_NPIVS_27

BARDA is seeking contractors to support the Vaccine Medical Countermeasures for Pandemic Influenza Preparedness and Response Program. The selected providers will be responsible for furnishing all necessary personnel, materials, and facilities to produce vaccines, antigens, and adjuvants for pandemic preparedness and public health emergencies. This includes generating and submitting critical analytical, clinical, and manufacturing data to the FDA to ensure rapid regulatory decisions and manufacturing readiness. To be eligible for this award, offerors must have experience producing vaccines against influenza and strains with pandemic potential. Mandatory qualifications include either holding a U.S. influenza vaccine license or demonstrating the development of an influenza vaccine through the submission of a Biologics License Application for seasonal or pandemic vaccines. This solicitation is managed by the Department of Health and Human Services with a response deadline of October 30, 2026.

Barda - Aspr / Daappo / Barda Dcma

POSTED

DEADLINE

Industry Day: DARPA Documentation & Decision Support Sprint (D2)

Solicitation # DARPA-SN-26-118

Defense Advanced Research Projects Agcy

POSTED

DEADLINE

DARPA Surgical Competition (DSC) Industry Day

Solicitation # DARPA-SN-26-125

Defense Advanced Research Projects Agcy

POSTED

DEADLINE

Human Hindbrain Organoid Functional Assay Services.

Solicitation # RFQ_CDR-2026-135968

The U.S. Food and Drug Administration, through the Center for Drug Evaluation and Research, intends to award a sole-source, firm-fixed-price purchase order to OrganoTherapeutics SARL for human iPSC-derived hindbrain organoid functional assay services. This acquisition, conducted under FAR Part 12 as a commercial service, aims to support in vitro research on drug-induced effects on respiratory-relevant neural circuits. The scope of work includes the provision of human hindbrain organoids and associated culture materials, with twelve scheduled deliveries to the FDA White Oak Campus in Silver Spring, Maryland. The first delivery will consist of 96 organoids, followed by eleven subsequent deliveries of 48 organoids each. The contractor will perform functional characterization at its own laboratory using three-dimensional multi-electrode array technology to assess electrophysiological responses to FDA-identified drug and reversal-agent combinations. Key deliverables include the raw and analyzed data, analysis files, and comprehensive study reports. The anticipated period of performance is 18 months from the date of award. Award will be based on best value, with technical capability and past performance weighted more heavily than price. All invoicing must be processed electronically through the U.S. Department of Treasury's Invoice Processing Platform.

FDA Office Of Acq Grant Svcs

POSTED

DEADLINE

Hypoxia Chamber Services

Solicitation # 80JSC026Q0008

NASA Johnson Space Center is soliciting combined synopsis and request for quotations under solicitation 80JSC026Q0008 for Hypoxia Chamber Services to support the Artemis Program. The objective is to investigate the physiological, cognitive, and clinical effects of mild hypobaric hypoxia through two 7-day test protocols involving continuous habitation for six subjects at air equivalent altitudes of 7,000 and 9,500 feet. The scope of work encompasses the provision of infrastructure, personnel, training, materials, and operational support. The contract is structured as a firm fixed price agreement with a base period from September 15, 2026, to September 30, 2027, and multiple option periods extending through March 1, 2030. The acquisition is open to all responsible sources under NAICS code 541714, with a size standard of 1,000 employees. Evaluation is based on a trade-off process where technical acceptability and past performance are significantly more important than price. Proposals must be submitted via email to the designated points of contact by October 1, 2026, following an extension granted in Amendment 0004. Key requirements include the submission of FAR 52.212-3 representations and certifications and adherence to specific submission criteria regarding team qualifications and risk assessment. The contract also incorporates strict guidelines regarding the protection of sensitive information and restrictions on funding activities with China.

NASA Johnson Space Center

POSTED

DEADLINE

Hypobaric Chamber Pilot Studies

Solicitation # 80JSC026Q0006

NASA Johnson Space Center is soliciting quotes under solicitation 80JSC026Q0006 for pilot hypobaric chamber testing facilities to support decompression sickness research. The primary objective is to validate non-NASA resources for safe prebreathe procedures and extravehicular activity to support Artemis mission planning. The base requirement consists of three test days, with a minimum of two subjects per day, collecting and recording data according to research protocols. The contract also includes six optional work items, including additional test days, inflight-like treatment preparation, elevated metabolic rate testing, pharmaceutical-enhanced prebreathe, and body temperature studies. The base period of performance runs from September 1, 2026, to September 30, 2027, with various option periods extending through March or September 2029. This is a small business set-aside acquisition under NAICS code 541714. Awards will be made based on a trade-off analysis where technical acceptability and past performance are significantly more important than price. Technical evaluation focuses on facility capabilities, medical support, team expertise, and the proposed schedule for subject throughput. Offerors must provide a price quotation using the provided pricing sheet, and quotes must remain valid for at least 90 days. Following several amendments, the final deadline for the submission of offers is October 1, 2026, at 1:00 p.m. Central Time. All submissions must be sent electronically to the designated points of contact.

NASA Johnson Space Center

POSTED

DEADLINE

Undiagnosed Diseases Network (UDN) Diagnostic Research Innovation CenterThe National Institutes of Health, through the NINDS, is forecasting the establishment of a Diagnostic Research Innovation Center to support the next phase of the Undiagnosed Diseases Network. This center will operate as part of a broader ecosystem including the Clinical and Data Coordinating Center, Networks of Diagnostic Excellence, and the NIH Undiagnosed Diseases Program. The primary objective of the center is to advance innovative diagnostic tools and strategies for both genomic and non-genomic conditions, which includes the systematic re-evaluation of unsolved cases from previous network phases. The center will focus on generating and testing diagnostic hypotheses by utilizing advanced sequencing, multi-omics, and gene function studies in animal and human in vitro models. By collaborating with various network stakeholders, the center aims to identify novel disease-associated genes, genomic variants, and new syndromes. This initiative seeks an integrated center featuring investigators with a history of scientific synergy and collaboration. While this is currently a forecast to allow potential applicants time to plan and establish partnerships, formal applications are not yet being solicited.

National Institutes Of Health

POSTED

DEADLINE

study entitled “Malaria and vector borne disease surveillance in the Colombia/Venezuela border”

Solicitation # ERP_1301373256

The Naval Medical Research Unit South in Lima, Peru, is seeking a provider to conduct a study focused on malaria and vector borne disease surveillance along the Colombia and Venezuela border. While the government has identified the Administrators of Tulane Educational Fund as the only vendor currently capable of supporting the entire requirement, they are issuing this notice to identify other capable sources before proceeding with a sole source award under FAR 13.106-1(b)(i). Interested parties must submit a capability statement including technical, management, and cost data to Genaro Vasquez via email by 12:00 PM local time on September 18, 2026. Submissions must be in Microsoft Word or PDF format, not exceed five pages, and use the subject line ERP_1301373256. The government will use these submissions to determine whether to pursue a competitive procurement or move forward with the intended sole source contract.

Naval Medical Research Center

POSTED

DEADLINE

Cryo-Electron Microscopy (Cryo-EM) Services

Solicitation # 75N98026Q01177

The National Institutes of Health Olao, under the Department of Health and Human Services, is seeking providers for Cryo-Electron Microscopy (Cryo-EM) Services under solicitation number 75N98026Q01177. This combined contract opportunity is categorized under NAICS code 541714 and is managed by the office located in Bethesda, Maryland. Interested parties must submit their responses by the deadline of September 16, 2026, at 6:00 PM. The primary point of contact for this procurement is Roxane S. Burkett.

National Institutes Of Health Olao

POSTED

DEADLINE

TIDAL: Target-Induced Droplet Assembly of Ligands

Solicitation # S-197478

Developed by Los Alamos National Laboratory, TIDAL (Target-Induced Droplet Assembly of Ligands) is a programmable protein-only material that utilizes nanobodies fused with encapsulation peptides to create dynamic, liquid-like droplets through phase separation. This technology allows for the precise concentration of binders upon encountering a target ligand, enabling a versatile platform for resin-free protein purification, high-sensitivity diagnostics, and the creation of slow-release drug depots. It can also function intracellularly to sequester and neutralize harmful proteins associated with viral infections or cancer. The technology is currently at TRL 3 with a patent pending and is available for exclusive or non-exclusive licensing through the Department of Energy contractor, Triad. Key market applications span biopharmaceutical manufacturing, therapeutics, and biotechnology. Interested parties can contact Caleb Ledgerwood or Lindsay Augustyn via the provided licensing email to explore commercial partnerships for this innovation.

Triad - DOE Contractor

POSTED

DEADLINE

Master Protocol Development & Adaptive Design

POSTED

DEADLINE

Phase I/II Clinical Trial Management & Execution

W6QK Acc-Apg

POSTED

8 days ago

DEADLINE

in 5 days

AI Contract Overview

The Food and Drug Administration is planning to award a sole source firm-fixed price purchase order to The University of Liverpool under simplified acquisition procedures for the sequencing of Bundibugyo virus disease during the 2026 outbreak, relying on FAR Part 6.103-1 which permits non-competitive procurement when only one responsible source exists. This action falls under the NAICS code 541714 for Research and Development in Biotechnology and is not open for competitive bidding, as the FDA has determined that The University of Liverpool is the only entity with the necessary expertise and capacity to meet the technical requirements for this highly specific viral sequencing effort. The contract is intended to support bioanalytical method development and sample analysis by providing critical reagents and reference standards for quantifying CYP enzyme substrates and metabolites in hepatocyte experiments during the outbreak response. Responses to this notice must be submitted by Ryan Alexander at ryan.alexander@fda.hhs.gov no later than 5:00 pm on July 29, 2026, and must include a detailed capability statement for any other organization seeking consideration, though the government retains full discretion to determine whether a response justifies competitive solicitation. The procurement is not a request for competitive quotes, and no set-aside is being applied. The contract will be administered from the FDA’s office in Rockville, Maryland, with performance primarily occurring in Liverpool, England, and the solicitation number is OC-2026-135667, issued on July 24, 2026.

General Info

FDA awards University of Liverpool sole-source contract for Bundibugyo virus sequencing in 2026.

Agency

Department Of Health And Human Services → Food And Drug AdministrationView Agency

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)View NAICS

Place of Performance

Liverpool, MD, GBR

Set-Aside

NONE

Documents

(0)

No documents available

AI Contract Breakdown

Uniform Contract Format

No contract breakdown available.

Cannot generate Contract Breakdown because no documents were found from this contract's source.

Timeline

PhaseClosed

PostedJul 24

special-notice

Response DeadlineJul 29

Deadline has passed

Submission Closed

07/29/2026, 09:00:00 PM UTC

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

AgencyDepartment Of Health And Human Services → Food And Drug Administration

Contacts2 people available

OfficeRockville, MD, 20841, USA

Organization / Agency

Department Of Health And Human Services → Food And Drug Administration

View Agency Profile

Office AddressRockville, MD, 20841, USA

Contacts

Ryan Alexander

contact@example.gov

Craig Wright

contact@example.gov

Full Description

Procurement Type: Sole Source Simplified Acquisition Procedures (SAP) Purchase Order for Commercial Items

Authority: FAR Part 6.103-1, Only One Responsible Source

Subject: Notice of Intent to Award a Sole Source Contract – Sequencing Bundibugyo virus disease (BDBV) in the 2026 outbreak

Description: The Food and Drug Administration (FDA) intends to award a Sole Source firm-fixed price purchase order to The University of Liverpool for the Sequencing Bundibugyo virus disease (BDBV) in the 2026 outbreak, in accordance with the authority under FAR Part 6.103-1, Only One Responsible Source. This procurement is being conducted under simplified acquisition procedures in accordance with FAR Part 12 (RFO). The NAICS Code for this action is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

The primary objective of this requirement is to obtain critical reagents such as procure reference standards and internal standards to perform bioanalytical method development and sample analysis to determine the quantification of CYP enzyme substrates/metabolites and transporter substrates in hepatocyte experiments.

Responses:

Responses to this notice should be sent to Ryan Alexander at ryan.alexander@fda.hhs.gov by 5:00 pm July 29, 2026. This notice is not a request for competitive quotes. Any other firms desiring consideration must fully identify their interest and capability of meeting the requirements by submitting a capability statement. Any response shall undergo review to determine if it can meet the requirements. A determination by the Government not to compete this proposed requirement based upon a response to this notice is solely within the discretion of the Government.